Section Arrow
Quote
SLN.NASDAQ
- Silence Therapeutics Plc
Quotes are at least 15-min delayed:2026/09/19 04:14 EDT
Regular Hours
Last
 12.2
-0.5 (-3.94%)
Day High 
12.74 
Prev. Close
12.7 
1-M High
15.28 
Volume 
1.14M 
Bid
12.03
Ask
12.35
Day Low
12.14 
Open
12.59 
1-M Low
12.1 
Market Cap 
789.36M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 13.37 
20-SMA 13.53 
50-SMA 12.47 
52-W High 17.5758 
52-W Low 4.19 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.29/-1.02
Enterprise Value
789.43M
Balance Sheet
Book Value Per Share
0.62
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
559.00K
Operating Revenue Per Share
0.58
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
RXRXRecursion Pharmaceuticals3.83+0.29+8.19%-- 
TCRTAlaunos Therapeutics Inc.1.2-0.4-25.00%-- 
ROIVRoivant Sciences Ltd39.77-0.21-0.53%-- 
SLXNSilexion Therapeutics Corp.0.4355+0.0555+14.61%-- 
IOVAIovance Biotherapeutics10.25+0.23+2.30%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.